TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22212110

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guide sheath (EBUS-GS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Computed tomography (CT)-guided percutaneous core biopsy
Number of subjects: 64

Group type: COMPARATOR
Intervention: CT-guided biopsy for lesions <2 cm
Number of subjects: 64
Study: 19757270

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (2 tabs of 200 microg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin (20 units at 10 cc/min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 100
Study: 17311834

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 40
Study: 15316789

Group type: EXPERIMENTAL
Intervention: Ability to stand on one foot
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Ability to squat down to touch the floor
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Self-assessed health ('very good' vs 'moderate' or poorer state of health)
Number of subjects: 1166
Study: 11394404

Group type: EXPERIMENTAL
Intervention: PTFE-based flosses
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nylon-based flosses
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nylon-based tape
Number of subjects: 27
Study: 9492965

Group type: EXPERIMENTAL
Intervention: ICD prophylaxis
Number of subjects: 900

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 900
Study: 7893589

Group type: EXPERIMENTAL
Intervention: Racemic mephenytoin coadministered with debrisoquine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Racemic mephenytoin coadministered with sparteine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Racemic mephenytoin
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Debrisoquine and sparteine metabolic ratios
Number of subjects: 106
Study: 2920499

Group type: EXPERIMENTAL
Intervention: Yohimbine (4 mg t.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 74014

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 22
Study: 31117864

Group type: EXPERIMENTAL
Intervention: Flexor carpi ulnaris to biceps motor branch transfer
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (randomly selected)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Preoperative flexor carpi ulnaris weakness (M<5)
Number of subjects: 91
Study: 27894929

Group type: EXPERIMENTAL
Intervention: Ultrasound disposable gastroscopy (TDG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional gastroscopy (CG)
Number of subjects: 48
Study: 25516462

Group type: EXPERIMENTAL
Intervention: LLETZ-cone
Number of subjects: 103

Group type: COMPARATOR
Intervention: SWETZ
Number of subjects: 103
Study: 23916321

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 21247415

Group type: EXPERIMENTAL
Intervention: Rye products (RK)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole grain rye (RK)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rye products and WK
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rye kernels (RK)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rye products
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High content of indigestible carbohydrates in breakfast products
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High breath H(2) (AUC 120-270 min)
Number of subjects: 10
Study: 20003300

Group type: EXPERIMENTAL
Intervention: Health coaching, home blood pressure monitoring, and home-titration of antihypertensive medications
Number of subjects: 300

Group type: COMPARATOR
Intervention: Health coaching plus home blood pressure monitoring
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (passive control group)
Number of subjects: 300
Study: 17258357

Group type: EXPERIMENTAL
Intervention: Pneumococcal protein D conjugate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16150956

Group type: EXPERIMENTAL
Intervention: Lactulose (30 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 8
Study: 14658595

Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound with contrast agents
Number of subjects: 72
Study: 10606362

Group type: EXPERIMENTAL
Intervention: Mannequin tender and swollen joint counts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RADAR tender and swollen joint counts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RADAR swollen joint counts
Number of subjects: 60
Study: 7740055

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 or 0.25 mg per capsule)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triazolam (0.0312-0.25 mg per capsule)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Experimenter-administered doses of triazolam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Same day ratings obtained while subjects were under the influence of triazolam
Number of subjects: 6
Study: 2289489

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 8
Study: 7023592

Group type: EXPERIMENTAL
Intervention: Physostigmine 0.375 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Arecoline 4 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Physostigmine 0.25 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Physostigmine 0.75 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Arecoline 2 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 11
Study: 31018173

Group type: EXPERIMENTAL
Intervention: Two-step stannous fluoride dentifrice and hydrogen peroxide whitening gel system, interactive oscillating-rotating electric toothbrush, and expanded polytetrafluoroethylene floss
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard sodium fluoride dentifrice and a manual toothbrush (Control)
Number of subjects: 52
Study: 26604072

Group type: COMPARATOR
Intervention: Finerenone 1-40 mg PEG solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Finerenone 10 mg IR tablet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Finerenone 80 mg (eight × finerenone 10 mg IR tablets)
Number of subjects: 60
Study: 24654350

Group type: EXPERIMENTAL
Intervention: Incremental sevoflurane induction method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fixed 8% sevoflurane induction method
Number of subjects: 100
Study: 22408123

Group type: EXPERIMENTAL
Intervention: GH treatment (0.01 mg/kg per day for the first week, 0.02 mg/kg per day for the second week, and 0.03 mg/kg per day for the third week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pegvisomant treatment (10 mg/day for the first week and 15 mg/day for the last two weeks)
Number of subjects: 12
Study: 20188634

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study: 18520979

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ) treatment withdrawal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Partial or no withdrawal of TBZ treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post hoc analysis of TBZ withdrawal
Number of subjects: 30
Study: 16135901

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg daily
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Efavirenz 800 mg daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Both groups (600 mg and 800 mg)
Number of subjects: 84
Study: 12374927

Group type: EXPERIMENTAL
Intervention: RSA RoekoSeal with laterally compacted gutta-percha (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RSA RoekoSeal with vertically compacted warm gutta-percha (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pulp Canal Sealer (Group 3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No sealer (Group 4)
Number of subjects: 80
Study: 11019950

Group type: EXPERIMENTAL
Intervention: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel (DSG/EE)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 30 microgram ethinyl estradiol combined with 75 microgram gestodene (GSD/EE)
Number of subjects: 241
Study: 7586338

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/d, titrated to 40 and then to 80 mg during the first 16 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 2175083

Group type: EXPERIMENTAL
Intervention: Dexamethasone and glycerol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lasix
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mannitol+
Number of subjects: 102
Study: 7021057

Group type: COMPARATOR
Intervention: Control group (normal dental treatment)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Test group (additional fortnightly professional prophylaxes)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Test + F group (prophylaxes plus fortnightly 2-min fluoride rinses)
Number of subjects: 25
Study: 31755431

Group type: EXPERIMENTAL
Intervention: Oral propranolol 1 mg/kg/day titrated to 3 mg/kg/day over 1 week, continued for 6 months and tapered over 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intralesional propranolol hydrochloride 1 mg/ml; 0.2 ml/cm, 3 doses 4-6 weeks apart
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between both groups
Number of subjects: 20
Study: 28258844

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 52
Study: 26116264

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab
Number of subjects: 57919

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab
Number of subjects: 57919

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF medications (ranibizumab and bevacizumab)
Number of subjects: 57919

Group type: COMPARATOR
Intervention: Control group following cataract surgery
Number of subjects: 57919
Study: 23778060

Group type: EXPERIMENTAL
Intervention: ECIG group (experienced EC users)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SM-S group (smokers smoking tobacco cigarettes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SM-E group (smokers using EC)
Number of subjects: 80
Study: 21846439

Group type: EXPERIMENTAL
Intervention: Estrogen cream (3 g of vaginal cream containing 1.875 g of conjugated estrogens for six weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo cream (comparable cream without estrogens for six weeks)
Number of subjects: 69
Study: 19210012

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD), 10 to 12 sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU), single-session intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD)
Number of subjects: 0
Study: 16424720

Group type: EXPERIMENTAL
Intervention: Semirecumbent position (target backrest elevation of 45 degrees)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Supine position (backrest elevation of 10 degrees)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 221

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 221
Study: 12601237

Group type: EXPERIMENTAL
Intervention: Intrauterine repair of myelomeningocele
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional postgestational repair of myelomeningocele
Number of subjects: 77
Study: 11291606

Group type: COMPARATOR
Intervention: Venous blood gasometry (vbg) after exercise of antebrachial muscles in diabetic patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Laser Doppler fluxometry (LDF) in diabetic patients
Number of subjects: 32
Study: 8664529

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymorphic nonsustained ventricular tachycardia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia in dilated cardiomyopathy and hypertrophic cardiomyopathy
Number of subjects: 0
Study: 1518670

Group type: EXPERIMENTAL
Intervention: Psychologically prepared group given atropine as premedication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group given narcotic-sedative premedication
Number of subjects: 0
Study: 6097117

Group type: EXPERIMENTAL
Intervention: Cefmenoxime (0.5 to 2.0 g every six hours)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cefoxitin (0.5 to 2.0 g every six hours)
Number of subjects: 59
Study: 30927417

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg/day
Number of subjects: 173

Group type: COMPARATOR
Intervention: Ganirelix 0.25 mg/day
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Ganirelix
Number of subjects: 173
Study: 28687937

Group type: EXPERIMENTAL
Intervention: Combined nutraceutical (red yeast rice 10 mg, phytosterols 800 mg, L-tyrosol 5 mg)
Number of subjects: 60
Study: 25448925

Group type: EXPERIMENTAL
Intervention: Transoral fundoplication (TF)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sham surgery with omeprazole (control)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups (TF and control)
Number of subjects: 129
Study: 23643425

Group type: EXPERIMENTAL
Intervention: Periodic electrical somatosensory stimulation (TENS) at 2 Hz
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Conventional exercise training (EXTR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (CTRL)
Number of subjects: 31
Study: 21682909

Group type: EXPERIMENTAL
Intervention: Nintendo WiiActive programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard gym-based rehabilitation
Number of subjects: 80
Study: 19555395

Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bisoprolol (5-10 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 16
Study: 16623990

Group type: EXPERIMENTAL
Intervention: Insertion of a central line
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Insertion of a urinary catheter
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Surgical site infection
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Population attributable fraction for urinary catheter
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Population attributable fraction for central line
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Population attributable fraction for surgical site infection
Number of subjects: 132
Study: 15572496

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system
Number of subjects: 59

Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium
Number of subjects: 59
Study: 11371728

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2-DG) infusion
Number of subjects: 39
Study: 9773262

Group type: EXPERIMENTAL
Intervention: EE/GSD
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: EE/NGM
Number of subjects: 46
Study: 8005128

Group type: EXPERIMENTAL
Intervention: Ramipril treatment for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 54
Study: 2585534

Group type: EXPERIMENTAL
Intervention: 3 ppm formaldehyde
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5 mg/m3 respirable activated carbon aerosol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 ppm formaldehyde plus activated carbon aerosol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 24
Study: 1094748

Group type: EXPERIMENTAL
Intervention: Topically-applied buphenin (in a gel basis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31911249

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vildagliptin
Number of subjects: 0
Study: 29846131

Group type: EXPERIMENTAL
Intervention: Combined video-based training and conditioning (COM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Separated conditioning and video-based training (SEP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conditioning only (CON)
Number of subjects: 20
Study: 28171710

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study: 26444689

Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training, 2-hour sessions every week since primary school entry.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no AMC training)
Number of subjects: 70
Study: 22762460

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa microtablets (LC-5)
Number of subjects: 11

Group type: COMPARATOR
Intervention: levodopa/carbidopa/entacapone (LCE)
Number of subjects: 11
Study: 21700646

Group type: EXPERIMENTAL
Intervention: Out-patient withdrawal programme
Number of subjects: 82

Group type: COMPARATOR
Intervention: In-patient withdrawal programme
Number of subjects: 82
Study: 18816001

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 48
Study: 15888605

Group type: EXPERIMENTAL
Intervention: Theta oscillations during episodic trace access
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LORETA source localization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Episodic encoding stages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow wave activity
Number of subjects: 0
Study: 12372443

Group type: EXPERIMENTAL
Intervention: GnRH agonist (3.75 mg i.m. every 28 days for 3 months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard controlled ovarian hyperstimulation
Number of subjects: 51
Study: 10674010

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 30 mg daily for 1 year
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 600, methotrexate 40, 5‐fluorouracil 600 mg/m2 i.v. every 4 weeks, 9 cycles) + TAM
Number of subjects: 634

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 600, methotrexate 40, 5‐fluorouracil 600 mg/m2 i.v. every 4 weeks, 9 cycles)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: CMF + TAM
Number of subjects: 634

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 634
Study: 7586959

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) monitoring
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 16
Study: 2038944

Group type: EXPERIMENTAL
Intervention: Three cannulated cancellous bone screws
Number of subjects: 33

Group type: COMPARATOR
Intervention: Screw-angle plate device
Number of subjects: 33
Study: 6108783

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 6432201

Group type: EXPERIMENTAL
Intervention: Restrictive episiotomy policy (episiotomy restricted to fetal indications)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Liberal episiotomy policy (episiotomy used more liberally to prevent perineal tears)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Restrictive episiotomy policy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Liberal episiotomy policy
Number of subjects: 1000
Study: 31937160

Group type: EXPERIMENTAL
Intervention: Rectal progesterone 200 mg daily until 36+6 weeks or spontaneous delivery
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo administered in a similar manner
Number of subjects: 160
Study: 31680085

Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with benzbromarone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 66
Study: 30672211

Group type: EXPERIMENTAL
Intervention: Pestle needling therapy, applied once daily for 4 weeks.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Routine treatment and nursing for diabetes (Control group).
Number of subjects: 132
Study: 26909824

Group type: EXPERIMENTAL
Intervention: Bifrontal ECT
Number of subjects: 65

Group type: COMPARATOR
Intervention: Right Unilateral ECT
Number of subjects: 65
Study: 24164872

Group type: EXPERIMENTAL
Intervention: EpiCell tampon
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tranexamic acid impregnated tampon
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ChitoHem tampon
Number of subjects: 31
Study: 22679715

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Western medicine (Bacillus licheniformis and Deanxit)
Number of subjects: 64
Study: 20638648

Group type: EXPERIMENTAL
Intervention: Uninformative onset cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color cue
Number of subjects: 0
Study: 18046717

Group type: EXPERIMENTAL
Intervention: 72 weeks of peginterferon-alpha2b (1.5 mug/kg/week) and ribavirin (800-1400 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 48 weeks of peginterferon-alpha2b (1.5 mug/kg/week) and ribavirin (800-1400 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 72 weeks of peginterferon-alpha2b and ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 48 weeks of peginterferon-alpha2b and ribavirin
Number of subjects: 0
Study: 16036011

Group type: EXPERIMENTAL
Intervention: Home telecare using a videophone for the management of acute exacerbations of COPD (intervention period: 2 weeks)
Number of subjects: 22